CMML highlights from ASH 2022 Published 2022-12-12 Download video MP4 360p Recommendations 1:00:54 What is Chronic Myelomonocytic Leukemia? -9/28/17 28:25 Treatment of CMML Including RAS Mutated - R Itzykson 04:58 Dr. Osman on Autoimmunity, Female Sex, and KRAS Mutations in CMML 03:05 Diagnosis and management of CMML 1:21:34 CMML - Diagnosis & Treatment :a presentation by consultant haematologist Dr. Daniel Wiseman 17:59 Chronic Myeloid Leukemia (CML) - Myeloproliferative Neoplasm (MPN) - Philadelphia Chromosome 03:46 Update on KOMET-001: identifying the optimal dose of ziftomenib for patients with R/R AML 05:07 Chronic Myelomonocytic Leukemia 01:52 Investigating luspatercept utilization patterns in lower-risk MDS 17:40 What happens to lonely people under anesthesia? 02:17 The role of CAR T-cell therapy for treating myeloma in the era of bispecific antibodies 42:14 Highlights from EHA 2024 - Updates on the Treatment of CLL 27:16 Diagnosis and Therapy of CMML in 2015 03:21 How long does someone live with AML? #AML 02:46 An update on emerging therapies for the treatment of polycythemia vera 03:18 What is blood cancer? 07:19 Mayo Clinic Explains Lymphoma 02:24 Differentiating Between Essential Tremor and Parkinson's Disease 02:11 Signs and Symptoms of Ovarian Cancer Similar videos 01:10 CMML: unmet needs and future outlooks 01:08 An insight into the mutational landscape and unique features of CMML 01:47 Epigenetic dysregulation in ASXL-1-mutant CMML 02:18 Insights into the diagnosis and prognosis of CMML 18:24 ASH 2022 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Aaron Goodman "Papa Heme" 03:20 Emerging treatment strategies for CMML 02:15 Safety and efficacy of ASTX727 in patients with CMML from Phase II and Phase III ASCERTAIN studies 1:04:24 Yale ASH 2022 Highlights: Myeloid Leukemia 02:26 Highlights in Waldenström’s macroglobulinemia at ASH 2022 01:14 Exciting updates in R/R multiple myeloma: highlights at ASH 2022 01:47 ASH CLL highlights: ibrutinib-venetoclax combination & undetectable MRD in IGHV-mutated patients 01:32 Phase II efficacy and safety results of ruxolitinib for patients with symptomatic CMML 04:26 Retrospective analysis of venetoclax-based therapy in CMML More results